Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Asston Pharmaceuticals IPO is a book build issue of ₹27.56 crores. The issue is entirely a fresh issue of 0.22 crore shares of ₹27.56 crore.
Asston Pharmaceuticals IPO bidding started from Jul 9, 2025 and ended on Jul 11, 2025. The allotment for Asston Pharmaceuticals IPO was finalized on Jul 14, 2025. The shares got listed on BSE SME on Jul 16, 2025.
Asston Pharmaceuticals IPO price band is set at ₹123.00 per share . The lot size for an application is 1,000. The minimum amount of investment required by an individual investor (retail) is ₹2,30,000.00 (2,000 shares). The minimum lot size investment for HNI is 3 lots (3,000 shares), amounting to ₹3,69,000.
Sobhagya Capital Options Pvt.Ltd. is the book running lead manager and Maashitla Securities Pvt.Ltd. is the registrar of the issue. The market maker of the company is JSK Securities & Services Pvt.Ltd..
Refer to Asston Pharmaceuticals IPO RHP for detailed Information.
| IPO Date | July 9, 2025 to July 11, 2025 |
| Listing Date | July 16, 2025 |
| Face Value | ₹10 per share |
| Issue Price Band | ₹115 to ₹123 per share |
| Issue Price Final | ₹123 per share |
| Lot Size | 1,000 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 22,41,000 shares (aggregating up to ₹27.56 Cr) |
| Reserved for Market Maker | 1,13,000 shares JSK Securities & Services Pvt.Ltd. (aggregating up to ₹1.39 Cr) |
| Net Offered to Public | 21,28,000 shares (aggregating up to ₹26.17 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Share Holding Pre Issue | 62,71,360 shares |
| Share Holding Post Issue | 85,12,360 shares |
Asston Pharmaceuticals IPO offers total 22,41,000 shares. Out of which 10,60,000 (47.30%) allocated to QIB, 4,25,000 (18.96%) allocated to QIB (Ex- Anchor), 3,22,000 (14.37%) allocated to NII, 7,46,000 (33.29%) allocated to RII and 6,35,000 (28.34%) allocated to Anchor investors.
| Investor Category | Shares Offered |
|---|---|
| Market Maker Shares Offered | 1,13,000 (5.04%) |
| QIB Shares Offered | 10,60,000 (47.30%) |
| − Anchor Investor Shares Offered | 6,35,000 (28.34%) |
| − QIB (Ex. Anchor) Shares Offered | 4,25,000 (18.96%) |
| NII (HNI) Shares Offered | 3,22,000 (14.37%) |
| − bNII > ₹10L | 2,15,000 (9.59%) |
| − sNII < ₹10L | 1,07,000 (4.77%) |
| Retail Shares Offered | 7,46,000 (33.29%) |
| Total Shares Offered | 22,41,000 (100.00%) |
Asston Pharmaceuticals IPO raises ₹7.81 crore from anchor investors. Asston Pharmaceuticals IPO Anchor bid date is July 8, 2025. Asston Pharmaceuticals IPO Anchor Investors list
| Bid Date | July 8, 2025 |
| Shares Offered | 6,35,000 |
| Anchor Portion Size (In Cr.) | 7.81 |
| Anchor lock-in period end date for 50% shares (30 Days) | August 13, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | October 12, 2025 |
Asston Pharmaceuticals IPO opens on July 9, 2025, and closes on July 11, 2025.
| IPO Open Date | Wed, Jul 9, 2025 |
| IPO Close Date | Fri, Jul 11, 2025 |
| Tentative Allotment | Mon, Jul 14, 2025 |
| Initiation of Refunds | Tue, Jul 15, 2025 |
| Credit of Shares to Demat | Tue, Jul 15, 2025 |
| Tentative Listing Date | Wed, Jul 16, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Fri, Jul 11, 2025 |
Investors can bid for a minimum of 2,000 shares and in multiples of 1,000 shares thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,46,000 |
| Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,46,000 |
| S-HNI (Min) | 3 | 3,000 | ₹3,69,000 |
| S-HNI (Max) | 8 | 8,000 | ₹9,84,000 |
| B-HNI (Min) | 9 | 9,000 | ₹11,07,000 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Incorporated in 2019, Asston Pharmaceuticals Limited is engaged in the business of pharmaceuticals, specializing in exporting healthcare products globally.
The company offers a diverse range of products, including tablets, capsules, sachets, and syrups. Its product portfolio encompasses various therapeutic categories, such as analgesics, antibiotics, antifungals, vitamins, and more.
The company manufactures pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis, primarily working on a principle-to-principle approach with various marketers.
The company is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing.
Products:
As of 3 July 2025, the company has 46 Permanent employees and 6 contractual employees in various departments.
Competitive Strengths:
Asston Pharmaceuticals Limited's revenue increased by 62% and profit after tax (PAT) rose by 218% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 31 May 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 31.83 | 28.12 | 20.26 | 13.69 |
| Total Income | 6.21 | 25.61 | 15.84 | 7.19 |
| Profit After Tax | 1.32 | 4.33 | 1.36 | 1.06 |
| EBITDA | 1.93 | 6.16 | 2.55 | 1.52 |
| Net Worth | 12.04 | 10.72 | 6.39 | 1.99 |
| Reserves and Surplus | 5.77 | 4.45 | 5.61 | 1.29 |
| Total Borrowing | 7.83 | 7.26 | 6.82 | 5.25 |
| Amount in ₹ Crore | ||||
The market capitalization of Asston Pharmaceuticals IPO is ₹104.70 Cr.
KPI as of Mon, Mar 31, 2025.
| KPI | Values |
|---|---|
| ROE | 50.56% |
| ROCE | 51.25% |
| Debt/Equity | 0.68 |
| RoNW | 40.36% |
| PAT Margin | 17.27% |
| EBITDA Margin | 24.60% |
| Price to Book Value | 12.07 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 6.90 | 9.32 |
| P/E (x) | 17.83 | 13.2 |
The Company Asston Pharmaceuticals IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|---|
| 1 | Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit | 6.00 |
| 2 | Funding the incremental working capital requirements of the Company | 13.00 |
| 3 | Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company | 1.00 |
| 4 | General Corporate Purposes | 3.95 |
[Dilip Davda] APL is engaged in manufacturing and exporting pharmaceutical formulations and nutraceutical products. It caters to various domestic and global customers with tailor made products. It also engaged third party contract manufacturers for certain critical products. The company posted growth in its top and bottom lines for the reported periods. However, sudden boost in bottom lines from FY25 onwards raise eyebrows and concern over its sustainability. It is operating in a highly competitive and fragmented segment. Small equity base post-IPO indicates longer gestation period for migration. Well-informed/cash surplus investors may park moderate fund for long term. Read detail review...
| Listing Date | July 16, 2025 |
| BSE Script Code | 544445 |
| NSE Symbol | |
| ISIN | INE0SJX01015 |
| Final Issue Price | ₹123 per share |
| BSE Listing Group | M |
| Price Details | BSE SME |
|---|---|
| Final Issue Price | ₹123.00 |
| Open | ₹119.00 |
| Low | ₹113.05 |
| High | ₹124.95 |
| Last Trade | ₹124.95 |
Asston Pharmaceuticals Ltd.
4th Floor, Office No. A-431 Balaji Bhavan,
Plot No 42A Sector-11 CBD Belapur,
Navi Mumbai, Thane
Navi Mumbai, Maharashtra, 400614
Phone: +91 22 49731411
Email: info@asstonpharmaceuticals.com
Website: http://www.asstonpharmaceuticals.com/
Maashitla Securities Pvt.Ltd.
Phone: +91-11-45121795-96
Email: ipo@maashitla.com
Website: https://maashitla.com/allotment-status/public-issues
Asston Pharmaceuticals IPO is a SME IPO of 22,41,000 equity shares of the face value of ₹10 aggregating up to ₹27.56 Crores. The issue is priced at ₹123 per share. The minimum order quantity is 1000.
The IPO opens on July 9, 2025, and closes on July 11, 2025.
Maashitla Securities Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE SME.
Zerodha customers can apply online in Asston Pharmaceuticals IPO using UPI as a payment gateway. Zerodha customers can apply in Asston Pharmaceuticals IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Asston Pharmaceuticals IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Asston Pharmaceuticals IPO opens on July 9, 2025 and closes on July 11, 2025.
Asston Pharmaceuticals IPO lot size is 1000, and the minimum amount required for application is ₹2,46,000, with 2 lots being the minimum application size.
You can apply in Asston Pharmaceuticals IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Asston Pharmaceuticals IPO will be done on Monday, July 14, 2025, and the allotted shares will be credited to your demat account by Tuesday, July 15, 2025. Check the Asston Pharmaceuticals IPO allotment status.
The Asston Pharmaceuticals IPO listing date is on Wednesday, July 16, 2025.
Useful Articles
RHP